SLP Simulations Plus

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Thursday, November 17, 2016, to shareholders of record as of Thursday, November 10, 2016.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.05 per share per quarter. Of course, the board always has the discretion of discontinuing, increasing, or decreasing the dividend in accordance with the cash needs of the business.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.

EN
31/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Simulations Plus

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

 PRESS RELEASE

Simulations Plus and Enabling Technologies Consortium Announce Strateg...

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform. The collaboration focuses on enhancing the predictive capabiliti...

 PRESS RELEASE

Simulations Plus Supported Development of Every FDA-Approved Drug in 2...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the . “For more than 25 years, our clients have entrusted us to provide the mission-critical software and services needed to develop therapies that are changing the landscape of healthcare,” said , Chief Executive Officer at Simulations Plu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch